COLLABORATION AGREEMENTS (Tables)

9 Months Ended

Sep. 30, 2018

The following table summarizes our total consolidated net revenues from collaborators, for the periods indicated, in thousands:

	Three Months Ended September 30,					Nine Months Ended September 30,
Description	2018			2017		2018		2017
Sanofi Genzyme	$	(1,560	)	$	14,603	$	40,370	$	41,255
Vir Biotechnology		2,957			—		10,313		—
MDCO		—			2,255		1,957		10,141
Other		212			238		775		592
Total net revenues from collaborators	$	1,609		$	17,096	$	53,415	$	51,988

Balance and Change in Contract Liabilities Related to Collaboration Agreements

The following table presents the balance of our contract liabilities related to our collaboration agreements at September 30, 2018 and January 1, 2018, in thousands:

At September 30,

2018

At January 1,

2018

Contract liabilities:

Deferred revenues

5,067

16,570

During the nine months ended September 30, 2018, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements, in thousands:

Revenue recognized in the period from:

Nine Months Ended

September 30, 2018

Amounts included in contract liability at the beginning of the period

14,953

Schedule of Research and Development Expenses Incurred by Type that are Directly Attributable to Each Agreement

The following table provides the research and development expenses incurred by type that are directly attributable to each agreement for the periods indicated, in thousands:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2018						2017						2018						2017
	Sanofi Genzyme		Vir		MDCO		Sanofi Genzyme		Vir		MDCO		Sanofi Genzyme		Vir		MDCO		Sanofi Genzyme		Vir		MDCO
Research and development
Clinical trial and manufacturing	$	4,308	$	800	$	937	$	42,772	$	—	$	307	$	32,403	$	6,851	$	1,578	$	127,127	$	—	$	5,402
External services		588		1,023		1		1,502		—		67		5,095		7,374		1		2,998		—		67
Other		395		—		2		1,394		—		—		1,145		980		2		4,384		—		24
Total research and development expenses	$	5,291	$	1,823	$	940	$	45,668	$	—	$	374	$	38,643	$	15,205	$	1,581	$	134,509	$	—	$	5,493

Prior Revenue Standard | ASU 2014-09 Revenue from Contracts with Customers

Revenue from Collaborators

The following table summarizes our total consolidated net revenues from collaborators, using the prior revenue standard, for the periods indicated, in thousands:

	Three Months Ended September 30,					Nine Months Ended September 30,
Description	2018			2017		2018		2017
Sanofi Genzyme	$	(862	)	$	14,603	$	86,107	$	41,255
Vir Biotechnology		2,957			—		10,313		—
MDCO		—			2,255		6,353		10,141
Other		212			238		775		592
Total net revenues from collaborators	$	2,307		$	17,096	$	103,548	$	51,988